论文部分内容阅读
目的:评价尿激酶治疗急性缺血性视神经病变的疗效。方法:将68例(82只眼)急性缺血性视神经病变随机分为尿激酶治疗组46只眼及对照组36只眼,随访期为2个月。结果:治疗组视力改善率93.5%,对照组为52.8%(P<0.005)。结论:结果提示尿激酶可能是治疗急性缺血性视神经病变的一种更为有效的药物。
Objective: To evaluate the efficacy of urokinase in the treatment of acute ischemic optic neuropathy. Methods: 68 cases (82 eyes) of acute ischemic optic neuropathy were randomly divided into urokinase group 46 eyes and control group 36 eyes, followed up for 2 months. Results: The visual acuity improvement rate was 93.5% in the treatment group and 52.8% in the control group (P <0.005). Conclusions: The results suggest that urokinase may be a more effective drug for the treatment of acute ischemic optic neuropathy.